Literature DB >> 23797309

Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy.

Kevin L Winthrop1, Michael Iseman.   

Abstract

In modern times a relationship between tuberculosis (TB) and rheumatoid arthritis (RA) has been firmly recognized, and is primarily attributable to the immunosuppressive therapies used to treat RA. Whereas TB can complicate the successful management of RA, nontuberculous mycobacteria have now perhaps become as important as (if not more so than) TB in the setting of RA, and can represent an even greater challenge to the rheumatologist wishing to use immunosuppressive therapies. This article reviews our most recent understanding of the epidemiological and clinical aspects of mycobacterial disease as it relates to RA, and the existing and emerging immunosuppressive therapies used to treat this disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23797309     DOI: 10.1038/nrrheum.2013.82

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  80 in total

1.  Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems.

Authors:  D Rebecca Prevots; Pamela A Shaw; Daniel Strickland; Lisa A Jackson; Marsha A Raebel; Mary Ann Blosky; Ruben Montes de Oca; Yvonne R Shea; Amy E Seitz; Steven M Holland; Kenneth N Olivier
Journal:  Am J Respir Crit Care Med       Date:  2010-06-10       Impact factor: 21.405

2.  Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy.

Authors:  Xavier Mariette; Gabriel Baron; Florence Tubach; Frédéric Lioté; Bernard Combe; Corinne Miceli-Richard; René-Marc Flipo; Philippe Goupille; Matthieu Allez; Dominique Salmon; Dominique Emilie; Guislaine Carcelain; Philippe Ravaud
Journal:  Ann Rheum Dis       Date:  2012-01-17       Impact factor: 19.103

3.  Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis.

Authors:  Joseph R Lutt; Mary L Pisculli; Michael E Weinblatt; Atul Deodhar; Kevin L Winthrop
Journal:  J Rheumatol       Date:  2008-08       Impact factor: 4.666

4.  An outbreak of mycobacterial furunculosis associated with footbaths at a nail salon.

Authors:  Kevin L Winthrop; Marcy Abrams; Mitchell Yakrus; Ira Schwartz; Janet Ely; Duncan Gillies; Duc J Vugia
Journal:  N Engl J Med       Date:  2002-05-02       Impact factor: 91.245

5.  Increased risk of nontuberculous mycobacterial infection in asthmatic patients using long-term inhaled corticosteroid therapy.

Authors:  Masayuki Hojo; Motoyasu Iikura; Satoshi Hirano; Haruhito Sugiyama; Nobuyuki Kobayashi; Koichiro Kudo
Journal:  Respirology       Date:  2012-01       Impact factor: 6.424

6.  Perturbation of the T cell repertoire in rheumatoid arthritis.

Authors:  U G Wagner; K Koetz; C M Weyand; J J Goronzy
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

7.  Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment.

Authors:  Teresa A Simon; Johan Askling; Diane Lacaille; Jarrod Franklin; Frederick Wolfe; Allison Covucci; Samy Suissa; Marc C Hochberg
Journal:  Arthritis Res Ther       Date:  2010-04-14       Impact factor: 5.156

8.  Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.

Authors:  Frederick Wolfe; Kaleb Michaud; Janice Anderson; Kathy Urbansky
Journal:  Arthritis Rheum       Date:  2004-02

Review 9.  Update on the epidemiology of pulmonary nontuberculous mycobacterial infections.

Authors:  Brian A Kendall; Kevin L Winthrop
Journal:  Semin Respir Crit Care Med       Date:  2013-03-04       Impact factor: 3.119

10.  Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.

Authors:  Juan J Gómez-Reino; Loreto Carmona; Vicente Rodríguez Valverde; Emilio Martín Mola; Maria Dolores Montero
Journal:  Arthritis Rheum       Date:  2003-08
View more
  23 in total

1.  Mycobacterial skin and soft tissue infection.

Authors:  Shu-Hua Wang; Preeti Pancholi
Journal:  Curr Infect Dis Rep       Date:  2014-11       Impact factor: 3.725

Review 2.  Obstructive lung diseases and risk of rheumatoid arthritis.

Authors:  H Maura Friedlander; Julia A Ford; Alessandra Zaccardelli; Alexsandra V Terrio; Michael H Cho; Jeffrey A Sparks
Journal:  Expert Rev Clin Immunol       Date:  2020-01-06       Impact factor: 4.473

Review 3.  Immunological roulette: Luck or something more? Considering the connections between host and environment in TB.

Authors:  John E Pearl; Mrinal Das; Andrea M Cooper
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530

Review 4.  [Nontuberculous mycobacterial infections].

Authors:  A Nowag; M Platten; G Plum; P Hartmann
Journal:  Z Rheumatol       Date:  2017-11       Impact factor: 1.372

5.  Risk for Mycobacterial Disease among Patients with Rheumatoid Arthritis, Taiwan, 2001-2011.

Authors:  Tsai-Ling Liao; Ching-Heng Lin; Gwan-Han Shen; Chia-Li Chang; Chin-Fu Lin; Der-Yuan Chen
Journal:  Emerg Infect Dis       Date:  2015-08       Impact factor: 6.883

6.  Risk of Tuberculosis in Children with Juvenile Idiopathic Arthritis: A Nationwide Population-Based Study in Taiwan.

Authors:  Yi-Chen Hsin; Lai-Zhen Zhuang; Kuo-Wei Yeh; Cheng-Wei Chang; Jorng-Tzong Horng; Jing-Long Huang
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

7.  Rheumatoid arthritis increases the risk of nontuberculosis mycobacterial disease and active pulmonary tuberculosis.

Authors:  Jun-Jun Yeh; Yu-Chiao Wang; Fung-Chang Sung; Chia-Hung Kao
Journal:  PLoS One       Date:  2014-10-22       Impact factor: 3.240

8.  QuantiFERON-TB Gold In-Tube assay for screening arthritis patients for latent tuberculosis infection before starting anti-tumor necrosis factor treatment.

Authors:  Hyun Lee; Hye Yun Park; Kyeongman Jeon; Byeong-Ho Jeong; Ji-Won Hwang; Jaejoon Lee; Hoon-Suk Cha; Eun-Mi Koh; Eun-Suk Kang; Won-Jung Koh
Journal:  PLoS One       Date:  2015-03-06       Impact factor: 3.240

Review 9.  Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis.

Authors:  K L Winthrop; S-H Park; A Gul; M H Cardiel; J J Gomez-Reino; Y Tanaka; K Kwok; T Lukic; E Mortensen; D Ponce de Leon; R Riese; H Valdez
Journal:  Ann Rheum Dis       Date:  2015-08-28       Impact factor: 19.103

Review 10.  '"Why me, why now?" Using clinical immunology and epidemiology to explain who gets nontuberculous mycobacterial infection.

Authors:  M Alexandra Lake; Lyn R Ambrose; Marc C I Lipman; David M Lowe
Journal:  BMC Med       Date:  2016-03-23       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.